Haemophilia: 5 things you need to know

  1. What is haemophilia? When you cut yourself, proteins called clotting factors combine with your blood cells called platelets to make the blood thick and sticky. This makes the bleeding stop. Haemophilia, a congenital lifelong bleeding disorder that prevents the blood from clotting properly, leads to patients bleeding internally, mostly in the joints, muscles and vital…

Needle that Completely Prevents Bleeding in Mice Could Benefit Hemophilia Patients

Researchers from South Korea have developed a new type of needle that is able to completely prevent bleeding following syringe needle puncture. The innovative new needle can be an valuable tool for people with blood clotting disorders like hemophilia where syringe injections can have significant side effects such as uncontrolled bleeding. The surface of the needles,…

Children with Severe Von Willebrand Disease and Haemophilia May Benefit from Treatments with Plasma Factors

Researchers reviewed the use of high-purity concentrates containing two plasma molecules that are lacking in patients with Von Willebrand disease (VWD), a hemorrhagic disorder. These products may be a good strategy for managing pediatric patients with VWD and hemophilia A (HA) who do not respond to other treatments. The study, “Human Von Willebrand Factor/Factor VIII Concentrates In The…

Advanced therapies for the treatment of hemophilia: future perspectives

Advanced therapies for the treatment of hemophilia In the future, the different types of advanced therapies such as gene therapy, cell therapy and tissue engineering, as well as the more recently developed induced pluripotent stem cells (iPSC) technology, may offer innumerable clinical applications for the treatment of certain monogenic diseases including hemophilia. True as it…

Dimension Announces Positive Preclinical Results for an Adeno-Associated Virus Delivery of Factor VIII in Hemophilia Treatment

Dimension Therapeutics recently revealed positive preclinical results from a novel adeno-associated virus (AAV) that delivers Factor VIII as a therapeutic approach for hemophilia A patients. The results were presented in a poster, titled “Optimized AAV-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice and Cynomolgus Macaques” at the 19th American Society of Gene and Cell Therapy (ASGCT)…

Initial Hemophilia B Treatments Should Be Done in Hospitals, Researchers Suggest

The initial treatment of patients newly diagnosed with hemophilia B should definitely be done in a hospital setting, according to a study conducted by scientists in Turkey. In the study, “Difficulties in the treatment of an Infant with Hemophilia B,” published in the Turkish archives of Pediatrics, Dr. Serdar Özkasap of Recep Tayyip Erdoğan University, School of…